Company / R&D Expense
Seres Therapeutics, Inc. R&D Expense History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$117.6M
FY2025
5-year range
$80.1M / $141.9M
FY2021-FY2025
Trend
-17.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has fluctuated over the past 10 years, ranging from $5M in FY2015 to $142M in FY2023.
Based on SEC 10-K filings.
$118M in FY2025 with a 10-year CAGR of +37.7%.
Improved from $91M to $118M over the past 3 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +9.1%
- 5-Year CAGR
- +4.2%
- 10-Year CAGR
- +37.7%
Key checks
Key Insights
- 5-year CAGR of +4.2%, indicating consistent growth.
- In FY2025, r&d expense decreased 17.1% year-over-year.
- Peak r&d expense was recorded in FY2023.
- Lowest r&d expense in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.18 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $117.6M | -17.1% |
| FY2023 | $141.9M | +56.7% |
| FY2022 | $90.6M | +13.0% |
| FY2021 | $80.1M | -16.5% |
| FY2020 | $96.0M | +7.3% |
| FY2019 | $89.5M | +9.1% |
| FY2018 | $82.0M | +115.2% |
| FY2017 | $38.1M | +255.4% |
| FY2016 | $10.7M | +123.1% |
| FY2015 | $4.8M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 24, 2026